Polyzois Makras
YOU?
Author Swipe
View article: Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future
Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future Open
Osteoporosis is a chronic disease associated with significant morbidity and mortality and requires long-term therapy. Efficacious and well-tolerated treatments are available, but their effect is either short-lived or lost following their d…
View article: Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review
Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review Open
Overall, there appears to be no deleterious effect of osteoporosis medications on fracture healing. The benefit of treating osteoporosis and the urgent necessity to mitigate imminent refracture risk after a fracture should be given prime c…
View article: Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment
Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment Open
View article: The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection Open
View article: Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab Open
Rebound-associated vertebral fractures (RVFx) following denosumab discontinuation are typically multiple, are commonly associated with acute sharp pain, increase the risk of imminent fractures, and are pathogenetically different from commo…
View article: Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study
Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study Open
The lipid profile is affected following menstrual cessation (MC). We aimed to evaluate the effects of goserelin-induced MC and subsequent menstrual restoration (MR) on lipid metabolism. Premenopausal women with histologically verified endo…
View article: Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece Open
Our study revealed that osteoporosis placed a considerable burden on QoL for postmenopausal women with severe osteoporosis in Greece. Patients reported valuing treatment efficacy, measured through reduction in future fractures and increase…
View article: Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited. Open
Adults with β- thalassemia major (β-TM) develop low BMD and fragility fractures at a higher incidence and at a younger age compared to the general population. The disease itself, including direct effects of anemia and iron overload toxicit…
View article: Impact of comorbidities on patterns and annual cost of anti-osteoporotic drug treatment based on real-world nation-wide data on 8,641,341 individuals
Impact of comorbidities on patterns and annual cost of anti-osteoporotic drug treatment based on real-world nation-wide data on 8,641,341 individuals Open
View article: Proportion of Patients Who Reach the BMD Surrogate Threshold Effect on Romosozumab: a Post Hoc Analysis of the Randomised FRAME and ARCH Phase 3 Trials
Proportion of Patients Who Reach the BMD Surrogate Threshold Effect on Romosozumab: a Post Hoc Analysis of the Randomised FRAME and ARCH Phase 3 Trials Open
View article: Current prevalence and patterns of anti-osteoporotic drug use based on real-world nation-wide data on 8,641,341 individuals
Current prevalence and patterns of anti-osteoporotic drug use based on real-world nation-wide data on 8,641,341 individuals Open
View article: International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults Open
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The exis…
View article: Adult Langerhans Cell Histiocytosis and the Skeleton
Adult Langerhans Cell Histiocytosis and the Skeleton Open
Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplasia in which somatic mutations in components of the MAPK/ERK pathway have been identified. Osseous involvement is evident in approximately 80% of all patients and may present…
View article: Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis
Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis Open
Vertebral fractures (VFs) are the most common type of osteoporotic fracture, and their prevalence and severity are key risk factors for future fragility fractures. Here, we assess the treatment effect of romosozumab on the incidence of new…
View article: Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients Open
View article: The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation Open
Context Zoledronate is used to prevent bone loss following denosumab discontinuation but its efficacy differs among studies. Objective To test if the duration of denosumab treatment affects the efficacy of subsequent zoledronate infusion. …
View article: Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss
Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss Open
The pathophysiology of human immunodeficiency virus (HIV)-associated bone loss is complex and to date largely unknown. In this study, we investigated serum expression of microRNAS (miRNAs) linked to bone metabolism in HIV-associated bone l…
View article: Investigating Denosumab discontinuation in the TgRANKL osteoporotic mouse model
Investigating Denosumab discontinuation in the TgRANKL osteoporotic mouse model Open
View article: Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study Open
Carfilzomib with dexamethasone (Kd) is a well-established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma-related bone disease. This non-interventional…
View article: Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review Open
Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered. However, its favorable skeletal effects reverse quickly upon i…
View article: Questions and facts regarding denosumab discontinuation among postmenopausal women
Questions and facts regarding denosumab discontinuation among postmenopausal women Open
In contrast to other chronic diseases where treatment is lifelong, in osteoporosis treatment discontinuation may be considered under certain conditions. Bisphosphonates (BPs) remain the mainstay of...
View article: Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder
Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder Open
The pathophysiology of chronic kidney disease–mineral and bone disorder (CKD-MBD) is complex and multifactorial. Recent studies have identified a link between microRNAs (miRNAs) and bone loss. In this study, we investigated the expression …
View article: Circulating and Tissue Expression Profile of <scp>MicroRNAs</scp> in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas
Circulating and Tissue Expression Profile of <span>MicroRNAs</span> in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas Open
We investigated the expression profile of selected microRNAs (miRs) in serum and tissue samples from patients with sporadic parathyroid adenomas (sPAs). This was a prospective, controlled cohort study. Forty patients with sPAs who had unde…
View article: The effect of sequential treatments on circulating microRNAs related to bone metabolism in women with postmenopausal osteoporosis
The effect of sequential treatments on circulating microRNAs related to bone metabolism in women with postmenopausal osteoporosis Open
View article: Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis
Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis Open
Context Serum expression of microRNAs (miRs) related to bone metabolism is affected by antiosteoporotic treatment. Objective To investigate the effect of sequential treatments on miR expression in postmenopausal women with osteoporosis. De…
View article: Gender Predilection in Sporadic Parathyroid Adenomas
Gender Predilection in Sporadic Parathyroid Adenomas Open
Primary hyperparathyroidism is a common endocrinopathy that is mainly caused by benign parathyroid adenomas. The frequency, clinical presentation and complications of the disease show significant differences between genders, with the major…
View article: Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation Open
Denosumab discontinuation has been associated with increased risk of rebound-associated multiple vertebral fractures. We report the cases of three patients, two females and one male, who had manifested rebound-associated vertebral fracture…
View article: OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis Open
Vertebral fractures (VFx) are the most common type of fracture in postmenopausal osteoporosis (PMO). VFx are generally classified using the Genant grading system as mild (grade 1), moderate (grade 2), or severe (grade 3) according to their…
View article: SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis Open
Depending on osteoporosis severity a long-term treatment, often in the form of a sequential regimen, may be required. The expression of microRNAs (miRs) related to bone metabolism in the serum is potentially affected by anti-osteoporotic t…
View article: Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study Open
Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorates quality of life. There are very limited data in the literature for the effect of chemother…